SPiKE Platform Candidates

About Oncopeptides

Oncopeptides is a commercial-stage biotech focused on developing targeted peptide-drug conjugates for oncology. Its core achievement is the full European marketing authorization of Pepaxti (melphalan flufenamide) for relapsed/refractory multiple myeloma, which is now generating revenue through direct commercialization in key European markets. The company's strategy is to drive adoption of Pepaxti, expand its label, and leverage its proprietary PDC and SPiKE platforms to advance new candidates, including an early-stage glioblastoma program with fast-track designation. Oncopeptides is publicly traded on Nasdaq Stockholm (ONCO).

Therapeutic Areas